Background Prostate‐specific membrane antigen (PSMA) is a well‐established therapeutic
and diagnostic target overexpressed in both primary and metastatic prostate cancers. PSMA …

144 Background: PSMA is a validated target that is overexpressed selectively on prostate
cancer cells. PSMA ADC is a fully human IgG1 antibody conjugated to the microtubule …

5023 Background: PSMA expression on prostate cancer cells provides a rationale for ADC
therapy. PSMA is a clinically validated target. PSMA ADC is a fully human antibody to PSMA …

Background Prostate‐specific membrane antigen (PSMA) is a well‐characterized target that
is overexpressed selectively on prostate cancer cells. PSMA antibody‐drug conjugate (ADC) …

PURPOSE Novel therapies are needed to extend survival in metastatic castration-resistant
prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA), a cell surface …

Aim Our aim was to evaluate overall survival and parameters prognosticating longer survival
in a large and homogeneous group of patients treated with 177 Lu-PSMA-617 radioligand …

279 Background: PSMA expression is increased in response to anti-androgen therapies and
is a promising therapeutic target for the treatment of prostate cancer (PCa). JNJ-081 is a …

Objective To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment
with 177Lu‐PSMA‐617, a novel radiolabelled small molecule that binds with high affinity to …

TPS211 Background:[177Lu] Lu-PSMA-617 (177Lu-PSMA-617) is a high-affinity prostate-
specific membrane antigen (PSMA)-targeted radioligand therapy that delivers β-particle …

BACKGROUND Antibody–drug conjugates (ADCs) are an emerging class of cancer
therapies that have demonstrated favorable activity both as single agents and as …